Drugmaker Merck seeks EU approval for $41B acquisition of Schering-Plough, expects ruling soonSeptember 21st, 2009 Merck seeks EU approval to buy Schering-PloughTRENTON, N.J. — Drugmaker Merck & Co.
Judge upholds Merck patent on blockbuster allergy drug Singulair, protecting sales till 2012August 19th, 2009 Judge rules for Merck on allergy drug's patentTRENTON, N.J. — The patent for Merck & Co.'s blockbuster allergy and asthma drug is valid, a federal judge ruled Wednesday, handing the drugmaker a crucial victory in its 2 1/2-year legal battle to block a rival from selling a cheaper generic version.
Watson Pharmaceuticals offering $850 million in mix of senior notesAugust 18th, 2009 Watson offering $850 million in notesMORRISTOWN, N.J. — Drug developer Watson Pharmaceuticals Inc.
Shareholders of Merck, Schering-Plough to vote on combination, would create No. 2 drugmakerAugust 7th, 2009 Merck takeover of Schering-Plough up for voteTRENTON, N.J. — Shareholders will decide Friday whether two New Jersey drug companies will become the world's second-biggest drugmaker.
Schering-Plough shareholders back $41.1 billion acquisition by partner Merck & Co.August 7th, 2009 Schering-Plough shareholders OK purchase by MerckTRENTON, N.J. — Shareholders of drugmaker Schering-Plough almost unanimously support being bought by bigger New Jersey neighbor Merck.
King Pharmaceuticals says 2nd quarter profit falls, but performance tops expectationsAugust 6th, 2009 King Pharmaceuticals reports 2Q profit dropBRISTOL, Tenn. — Drug developer King Pharmaceuticals said Thursday its second-quarter profit dropped, as generic competition continued to hurt drug sales.
Merck, Schering to pay $5.4M to resolve probes by 35 states into cholesterol drug studiesJuly 15th, 2009 Merck and Schering-Plough settle investigationNEW YORK — Drugmakers Merck & Co. and Schering-Plough Corp.
Federal agents contact maker of drug in Jackson probe; company recalls batches of propofolJuly 14th, 2009 Batch of drug central to Jackson probe recalledLOS ANGELES — Federal drug enforcement officials have contacted the maker of the powerful anesthetic propofol (PRO-puh-fall) as part of their investigation into Michael Jackson's death. A spokeswoman for Teva Pharmaceuticals says the Drug Enforcement Administration asked the company about a specific batch of the drug.
AIG, Merck, YRC Worldwide, Saks, Sprint Nextel are among big market movers ThursdayJuly 9th, 2009 AIG, Merck, YRC Worldwide are big moversNEW YORK — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and Nasdaq Stock Market:
NYSE:
American International Group Inc., down $3.62 at $9.48
An analyst said the insurer's equity may be zero due to risk of continued losses from credit default swaps and assets sold cheaply. Emulex Corp., down 76 cents at $8.94
Broadcom Corp.
Merck, Portola Pharmaceuticals sign deal worth up to $470 million to develop anticlotting drugJuly 9th, 2009 Merck, Portola in $470M deal for anticlotting drugTRENTON, N.J. — Merck & Co.
Merck and Schering-Plough say antitrust regulators want more details on $41.1B combinationJune 22nd, 2009 FTC requests more info from Merck, Schering-PloughNEW YORK — Drugmakers Merck and Co. and Schering-Plough Corp., which are in the process of a $41.1 billion tie-up, said Monday the Federal Trade Commission has asked for more information about the deal.
Watson Pharmaceuticals to buy private generic drug maker Arrow Group for $1.75B in cash, stockJune 17th, 2009 Watson Pharma to buy Arrow group for $1.75BNEW YORK — Watson Pharmaceuticals Inc. said Wednesday it will buy smaller generic drug maker Arrow Group for $1.75 billion in cash and stock.
Merck's heart failure drug rolofylline misses main and backup goals in late-stage trialJune 5th, 2009 Merck's heart failure drug misses trial goalsWHITEHOUSE STATION, N.J. — Merck says its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.
Merck mulls selling off veterinary products, its own or Schering-Plough's, before $41B mergerJune 3rd, 2009 Merck may sell animal drug assets before mergerWHITEHOUSE STATION, N.J. — Drugmaker Merck & Co.
Schering-Plough's 1st-quarter profit surges on lower costs, offsetting decline in salesApril 21st, 2009 Schering-Plough 1Q profit jumps despite sales fallNEW YORK — Schering-Plough Corp., in the process of being acquired by competitor Merck & Co., said Tuesday drug sales fell in the first quarter but profit tripled because of cost cutting and a charge in last year's quarter related to an acquisition. The Kenilworth, N.J.-based maker of arthritis treatment Remicade and allergy spray Nasonex earned $767 million, or 46 cents per share.
Loading ...